Rajan Jog
Overview
Explore the profile of Rajan Jog including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
138
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Muthumula C, Khare S, Jog R, Wickramaratne B, Lee A, Chakder S, et al.
Int J Pharm X
. 2024 May;
7:100254.
PMID: 38774112
Zileuton is a leukotriene inhibitor used to treat asthma. As a BCS class II drug it exhibits challenges with solubility which likely impact its absorption. As patient gender significantly impacts...
2.
Khare S, Jog R, Bright A, Burgess D, Chakder S, Gokulan K
Nanotoxicology
. 2023 Dec;
17(10):583-603.
PMID: 38146991
Nanocrystal drug formulation involves several critical manufacturing procedures that result in complex structures to improve drug solubility, dissolution, bioavailability, and consequently the efficacy of poorly soluble Biopharmaceutics Classification System (BCS)...
3.
Li T, Wan B, Jog R, Costa A, Burgess D
Int J Pharm
. 2021 Dec;
613:121384.
PMID: 34919998
Spray-dried pectin microparticles can potentially improve the oral bioavailability of peptides by virtue of their mucoadhesion. However, developing such formulations with desirable quality attributes is challenging due to the sensitivity...
4.
Andhariya J, Jog R, Shen J, Choi S, Wang Y, Zou Y, et al.
J Control Release
. 2019 Oct;
314:25-37.
PMID: 31654687
Development of IVIVCs is a very complicated process, especially for complex drug products such as parenteral PLGA microspheres with multiphasic drug release characteristics. Specifically, microspheres that exhibit an initial burst...
5.
Pace J, Jog R, Burgess D, Hadden M
J Liposome Res
. 2019 Oct;
30(3):305-311.
PMID: 31576768
Itraconazole (ITZ) is an FDA-approved antifungal agent that has recently been explored for novel biological properties. In particular, ITZ was identified as a potent inhibitor of the hedgehog (Hh) pathway,...
6.
Andhariya J, Jog R, Shen J, Choi S, Wang Y, Zou Y, et al.
J Control Release
. 2019 Jul;
308:1-13.
PMID: 31301338
Peptide loaded PLGA microsphere products are more complex in terms of manufacturing, drug release characteristics as well as release mechanism compared to small molecule loaded PLGA microsphere products. This is...
7.
Jog R, Burgess D
Int J Pharm
. 2019 Apr;
564:426-460.
PMID: 31026489
The novelty of the present research is application of a comprehensive quality by design (QbD) approach to minimize errors in product optimization and validation for the development of a stable...
8.
Jog R, Burgess D
Int J Pharm
. 2018 Oct;
553(1-2):238-260.
PMID: 30359685
Most of the recent drug compounds coming out of the drug discovery pipeline are labile (multiple polymorphs), and need to be developed into robust marketed oral drug formulations. There are...
9.
Bao Q, Shen J, Jog R, Zhang C, Newman B, Wang Y, et al.
Int J Pharm
. 2017 May;
526(1-2):145-156.
PMID: 28461266
It is essential as well as challenging to develop a reliable in vitro release testing method for determining whether differences in release profiles exist between qualitatively and quantitatively equivalent ophthalmic...
10.
Bao Q, Jog R, Shen J, Newman B, Wang Y, Choi S, et al.
Int J Pharm
. 2017 Mar;
523(1):310-319.
PMID: 28344172
The investigation of semisolid ophthalmic ointments is challenging due to their complex physicochemical properties and the unique anatomy of the human eye. Using Lotemax as a model ophthalmic ointment, three...